A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2023-02-21
Adverse events
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-04-11 (study day 30); relationship: not assessed
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-04-17 (study day 36); relationship: N
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-04-25 (study day 44); relationship: not assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-05-01 (study day 50); relationship: N
Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-07-02 (study day 112); relationship: not assessed
Grade 1 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-07-08 (study day 118); relationship: not assessed
Grade 3 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-11 (study day 121); relationship: N; serious criteria: hospitalization
Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-24 (study day 134); relationship: not assessed
Data queries
No data queries.